DexCom
Glucose-monitor maker DexCom Inc. (NASDAQ:DXCM) was among the top three gainers within the healthcare sector on July 28, advancing 2.33% in the season after gapping higher at the open. Key Points DexCom reported strong second-quarter results, beating Wall Street’s expectations.Earnings increased by 100% to 34 cents per share, and revenue rose by 25% to $871.3 million.The company raised its full-year revenue guidance to $3.5 billion to $3.55 billion, an increase of 21% at the midpoint.DexCom projects $4 billion to $4.5 billion in revenue for 2024 and $4.6 billion to $5.1 billion for 2025.Wall S...
ValueWalk
Key Points Dexcom is aiming for growth, and this year showcased its G7 sensors in a Super Bowl commercial.The company’s stock recently cleared a price consolidation above a $126.54 buy point, reaching its best levels in over a year.Heavy upside volume in recent weeks indicates strong institutional buying and market confidence about DexCom’s prospects.Analysts project strong double-digit earnings growth for DexCom this year and next.With expanded reimbursements, the market of potential users for DexCom now includes the majority of U.S. diabetes patients.5 stocks we like better than DexComYou ge...
ValueWalk
DexCom, Inc recently received FDA approval for their new G7 continuous glucose monitorThe improved device–and the relationships it is helping them build-show great promise for the future.DexCom stock has been struggling, but this news may be a catalyst.DexCom, Inc. (NASDAQ:DXCM) is a continuous glucose monitoring (CGM) company. In early December, they received approval from the United States Food and Drug Administration (FDA) for their new monitor, the G7. This device assists patients with Type 1 and Type 2 diabetes and gestational diabetes. Furthermore, the seemingly simple, all-in-one wearab...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら